A Quote, Financials, Valuation and Earnings

Azenta has a net margin of 18.92% compared to Agilent Technologies's net margin of -9.04%. Agilent Technologies's return on equity of 20.82% beat Azenta's return on equity of -7.97%.

Agilent Technologies has a consensus price target of $142.76, signalling upside risk potential of 34.33%. On the other hand Azenta has an analysts' consensus of $51.60 which suggests that it could grow by 93.04%. Given that Azenta has higher upside potential than Agilent Technologies, analysts believe Azenta is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.189, which suggesting that the stock is 18.904% more volatile than S&P 500. In comparison Azenta has a beta of 1.660, suggesting its more volatile than the S&P 500 by 66.003%.

Agilent Technologies has a quarterly dividend of $0.25 per share corresponding to a yield of 0.91%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Azenta quarterly revenues of $147.5M. Agilent Technologies's net income of $318M is higher than Azenta's net income of -$13.3M. Notably, Agilent Technologies's price-to-earnings ratio is 24.43x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 4.70x versus 2.08x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 18.92% compared to Agilent Technologies's net margin of -107.24%. Agilent Technologies's return on equity of 20.82% beat Bio-Rad Laboratories's return on equity of -23.87%.

Agilent Technologies has a consensus price target of $142.76, signalling upside risk potential of 34.33%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $353.17 which suggests that it could grow by 45.56%. Given that Bio-Rad Laboratories has higher upside potential than Agilent Technologies, analysts believe Bio-Rad Laboratories is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.189, which suggesting that the stock is 18.904% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 1.119, suggesting its more volatile than the S&P 500 by 11.924%.

Agilent Technologies has a quarterly dividend of $0.25 per share corresponding to a yield of 0.91%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Bio-Rad Laboratories quarterly revenues of $667.5M. Agilent Technologies's net income of $318M is higher than Bio-Rad Laboratories's net income of -$715.8M. Notably, Agilent Technologies's price-to-earnings ratio is 24.43x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 4.70x versus 2.67x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 18.92% compared to Agilent Technologies's net margin of 1.4%. Agilent Technologies's return on equity of 20.82% beat Bruker's return on equity of 6.78%.

Agilent Technologies has a consensus price target of $142.76, signalling upside risk potential of 34.33%. On the other hand Bruker has an analysts' consensus of $60.13 which suggests that it could grow by 53.9%. Given that Bruker has higher upside potential than Agilent Technologies, analysts believe Bruker is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.189, which suggesting that the stock is 18.904% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Agilent Technologies has a quarterly dividend of $0.25 per share corresponding to a yield of 0.91%. Bruker offers a yield of 0.51% to investors and pays a quarterly dividend of $0.05 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Bruker quarterly revenues of $979.6M. Agilent Technologies's net income of $318M is higher than Bruker's net income of $13.7M. Notably, Agilent Technologies's price-to-earnings ratio is 24.43x while Bruker's PE ratio is 51.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 4.70x versus 1.73x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 18.92% compared to Agilent Technologies's net margin of 0.07%. Agilent Technologies's return on equity of 20.82% beat Harvard Bioscience's return on equity of -18.36%.

Agilent Technologies has a consensus price target of $142.76, signalling upside risk potential of 34.33%. On the other hand Harvard Bioscience has an analysts' consensus of $4.50 which suggests that it could grow by 1093.95%. Given that Harvard Bioscience has higher upside potential than Agilent Technologies, analysts believe Harvard Bioscience is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.189, which suggesting that the stock is 18.904% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.468, suggesting its more volatile than the S&P 500 by 46.794%.

Agilent Technologies has a quarterly dividend of $0.25 per share corresponding to a yield of 0.91%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Harvard Bioscience quarterly revenues of $24.6M. Agilent Technologies's net income of $318M is higher than Harvard Bioscience's net income of $18K. Notably, Agilent Technologies's price-to-earnings ratio is 24.43x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 4.70x versus 0.17x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.